Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07164469 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07164469: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07164469 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07164469, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rimiducid (AP1903)
- DRUG CD70.CAR NK Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-06-28 |
| Est. Completion | 2033-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07164469
The ClinicalTrials.gov registry entry for NCT07164469 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07164469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07164469 about?
NCT07164469 is a clinical study titled "Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma". This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
What is the current status of trial NCT07164469?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-06-28. Estimated completion is 2033-09-30.
What interventions are being tested in trial NCT07164469?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rimiducid (AP1903) (DRUG), CD70.CAR NK Cells (DRUG).
Who is sponsoring clinical trial NCT07164469?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.